<DOC>
	<DOCNO>NCT01310036</DOCNO>
	<brief_summary>This open-label , single arm study evaluate safety efficacy Tarceva ( erlotinib ) first-line therapy patient stage IV recurrent non-small cell lung cancer harbour epidermal growth factor receptor ( EGFR ) mutation . All patient receive Tarceva 150 mg daily orally disease progression unacceptable toxicity occur . At investigator 's discretion , patient may receive Tarceva beyond disease progression .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) First Line Therapy Patients With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor ( EGFR ) Mutations</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Stage IV recurrent nonsmall cell lung cancer ( NSCLC ) Presence mutation ( ) exon 18 exon 21 epidermal growth factor receptor ( EGFR ) , ( except T790M single mutation ) Measurable disease ( least one lesion &gt; = 10 mm long diameter ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate hematological , renal liver function Patients T790M single mutation Prior exposure agent direct human epidermal receptor ( HER ) axis , e.g . erlotinib , gefitinib , cetuximab , trastuzumab Prior chemotherapy systemic anticancer therapy advance NSCLC disease Symptomatic uncontrolled central nervous system ( CNS ) metastases Other malignancy within last 5 year , except carcinoma situ cervix , basal squamous cell carcinoma skin , surgically treat localized prostate cancer , surgically treat ductal cell carcinoma situ breast Any significant ophthalmologic abnormality Preexisting parenchymal lung disease pulmonary fibrosis Use coumarins ( anticoagulation therapy use low molecular weight heparin recommend instead )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>